Kidney Health: Eat Well, Live Well Program for Chronic Kidney Disease

This study is testing a program called "Kidney Health: Eat Well, Live Well" for adults with early-stage chronic kidney disease (CKD, stages 2 or 3). The program aims to help you eat healthier to slow down kidney damage. If you join, you might receive kidney-friendly produce deliveries, recipes, grocery store gift cards, educational materials, and support from a "Health Partner." Researchers will compare these participants to those who receive educational materials and usual care. The main goal is to see if the program reduces kidney injury, measured by a urine test (UACR), and improves heart health, mental well-being, and diet quality. This study is for adults aged 18 and older who are patients at specific Harris Health clinics.

Study design: This is a randomized study with 330 participants, meaning you would be randomly assigned to either receive the program or educational materials and usual care.
What's involved: If you join the program, you would receive support and resources over 6 months, including calls and deliveries. You would also have clinic visits for data collection at the start, 3 months, and 6 months.
Compensation: You may receive e-gift cards to a grocery store of your choice as part of the intervention.
Follow-up: Your kidney health and other factors will be measured at the start, 3 months, and 6 months after joining the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Kidney Health: Eat Well, Live Well

Recruiting

NAAges 18+InterventionalHealth services

University of Texas at Austin

~330 participants

Updated 2025-03-26 on ClinicalTrials.gov

What's tested:1. Welcome package2. Welcome information (phone or text)3. Produce delivery + Recipes customized to produce4. E-gift cards to a grocery store of choice5. Personalized practical & emotional support through a dedicated health partner

At a glance

Recruiting sites

3 of 3 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Urine albumin:creatinine ratio (UACR)

Measured over Baseline, 3 months, 6 months

Conditions

Chronic Kidney Diseases

NCT05970341

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Harris Health System's Martin Luther King Jr. Health Center
Houston, Texasno site contact published
Recruiting
Harris Health System's Outpatient Center
Houston, Texasno site contact published
Recruiting
Harris Health System's Smith Clinic
Houston, Texasno site contact published
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Maninder Kahlon, PhD · PRINCIPAL_INVESTIGATOR · University of Texas at Austin

Who to contact

Courtney Mulligan, MA

[email protected]

512-522-4349

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Adult (18 years of age or older)

Primary care visit at either one of the three partner clinics from Harris Health \[Smith Clinic, Harris Health Outpatient Center (located on the LBJ campus), or Martin Luther King Jr. Health Center (MLK)\] and a primary care patient within Harris Health System

Have had at least 1 visit in the past 18 months with prior history in the clinic (i.e., not first visit)

Diagnosis of CKD (Stage 2, 3a, and 3b) as defined by estimated Glomerular Filtration Rate (eGFR) ≥ 30 and \<90 mL/min/1.73 m2 OR CDK 1 or undiagnosed with urine Albumin Creatinine Ratio ≥ 30 mg/g

Within the past 12 months, the most current serum K+ ≤ 4.6 mEq/L

English or Spanish speaking

Ability to participate in the program at least 6 months

Ability to clean, prepare, refrigerate/freeze food products that are given to them

Have access to receive SMS text messages

Location of preferred produce bag delivery within an available delivery zone

Exclusion

CKD 4, ESRD or on dialysis.

Taking certain medications chronically (more than twice a week for 90 days) that may interfere with K+ metabolism (such as non-steroidal anti-inflammatory drugs (NSAIDs), as self-reported during enrollment screening

Taking mineralocorticoid receptor antagonists

Taking Warfarin

Diagnosis of any specific kidney conditions (such as polycystic kidney disease, glomerulonephritis, Lupus associated with Nephritis, Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)) that would contraindicate study participation as determined by physician

Medical history of organ transplant that would contraindicate study participation as determined by physician

Received immunotherapy for primary or secondary kidney disease within 6 months prior to enrolment

Diagnostic of heart failure conditions Class IV in the New York Heart Association (NYHA) functional classification

Had myocardial infarction, unstable angina, stroke, or transient ischemic attack (TIA) within 12 weeks prior to enrolment

Had coronary revascularization (PCI, CABG) or valvular repair within 12 weeks prior to enrolment

On active hospice care as self-reported during enrollment screening

Diagnosis of active malignancy requiring treatment that would contraindicate study participation as determined by physician

Has decompensated cirrhosis as determined by physician

Cognitive impairment that would contraindicate study participation as self-reported during enrollment screening

What this trial measures

Urine albumin:creatinine ratio (UACR)Baseline, 3 months, 6 months
Marker of kidney damage and a useful predictor of cardiovascular (CV) events in adults. Uses spot urine to estimate 24-hour urine albumin excretion. UACR \> 30 mg/g indicates kidney damage.

Trialytics